Cresco Labs Analyst Ratings
Cresco Labs Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/24/2023 | 700.56% | Cantor Fitzgerald | → $14.25 | Maintains | Overweight |
| 12/30/2022 | 700.56% | Cantor Fitzgerald | $15 → $14.25 | Maintains | Overweight |
| 12/20/2022 | 40.45% | Cowen & Co. | $7 → $2.5 | Downgrades | Outperform → Market Perform |
| 12/02/2022 | 152.81% | Wedbush | → $4.5 | Initiates Coverage On | → Outperform |
| 08/18/2022 | 237.08% | Piper Sandler | $9 → $6 | Maintains | Overweight |
| 08/18/2022 | 742.7% | Cantor Fitzgerald | $19 → $15 | Maintains | Overweight |
| 03/24/2022 | 405.62% | Piper Sandler | $14 → $9 | Maintains | Overweight |
| 11/15/2021 | 967.42% | Cantor Fitzgerald | $12 → $19 | Maintains | Overweight |
| 11/03/2021 | 574.16% | Cantor Fitzgerald | $12.65 → $12 | Maintains | Overweight |
| 08/05/2021 | 658.43% | Cantor Fitzgerald | $21.5 → $13.5 | Maintains | Overweight |
| 07/07/2021 | 1922.47% | Jefferies | → $36 | Initiates Coverage On | → Buy |
| 01/20/2021 | 1079.78% | Cantor Fitzgerald | $18 → $21 | Maintains | Overweight |
| 11/19/2020 | 911.24% | Cantor Fitzgerald | $16 → $18 | Maintains | Overweight |
| 10/30/2020 | 798.88% | Cantor Fitzgerald | $15 → $16 | Maintains | Overweight |
| 08/21/2020 | 742.7% | Cantor Fitzgerald | $11 → $15 | Maintains | Overweight |
| 06/12/2020 | 135.96% | Needham | → $4.2 | Initiates Coverage On | → Hold |
| 05/29/2020 | 517.98% | Cantor Fitzgerald | $9.5 → $11 | Maintains | Overweight |
| 05/27/2020 | 433.71% | Cantor Fitzgerald | $8 → $9.5 | Maintains | Overweight |
| 04/28/2020 | 349.44% | Cantor Fitzgerald | $10 → $8 | Maintains | Overweight |
| 03/30/2020 | 461.8% | Cantor Fitzgerald | $12 → $10 | Maintains | Overweight |
| 02/14/2020 | 574.16% | Cantor Fitzgerald | → $12 | Initiates Coverage On | → Overweight |
| 09/13/2019 | 686.52% | Cowen & Co. | → $14 | Initiates Coverage On | → Outperform |
| 08/13/2019 | 517.98% | Piper Sandler | → $11 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 02/24/2023 | 700.56% | 康托·菲茨杰拉德 | → $14.25 | 维护 | 超重 |
| 12/30/2022 | 700.56% | 康托·菲茨杰拉德 | $15 → $14.25 | 维护 | 超重 |
| 12/20/2022 | 40.45% | 考恩公司 | $7 → $2.5 | 评级下调 | 跑赢→市场表现 |
| 12/02/2022 | 152.81% | 韦德布什 | → $4.5 | 开始承保 | →跑赢大盘 |
| 08/18/2022 | 237.08% | 派珀·桑德勒 | $9 → $6 | 维护 | 超重 |
| 08/18/2022 | 742.7% | 康托·菲茨杰拉德 | $19 → $15 | 维护 | 超重 |
| 03/24/2022 | 405.62% | 派珀·桑德勒 | $14 → $9 | 维护 | 超重 |
| 11/15/2021 | 967.42% | 康托·菲茨杰拉德 | $12 → $19 | 维护 | 超重 |
| 11/03/2021 | 574.16% | 康托·菲茨杰拉德 | $12.65 → $12 | 维护 | 超重 |
| 08/05/2021 | 658.43% | 康托·菲茨杰拉德 | $21.5 → $13.5 | 维护 | 超重 |
| 07/07/2021 | 1922.47% | 杰富瑞 | → $36 | 开始承保 | →购买 |
| 01/20/2021 | 1079.78% | 康托·菲茨杰拉德 | $18 → $21 | 维护 | 超重 |
| 11/19/2020 | 911.24% | 康托·菲茨杰拉德 | $16 → $18 | 维护 | 超重 |
| 10/30/2020 | 798.88% | 康托·菲茨杰拉德 | $15 → $16 | 维护 | 超重 |
| 08/21/2020 | 742.7% | 康托·菲茨杰拉德 | $11 → $15 | 维护 | 超重 |
| 06/12/2020 | 135.96% | 李约瑟 | → $4.2 | 开始承保 | →保留 |
| 05/29/2020 | 517.98% | 康托·菲茨杰拉德 | $9.5 → $11 | 维护 | 超重 |
| 05/27/2020 | 433.71% | 康托·菲茨杰拉德 | $8 → $9.5 | 维护 | 超重 |
| 04/28/2020 | 349.44% | 康托·菲茨杰拉德 | $10 → $8 | 维护 | 超重 |
| 03/30/2020 | 461.8% | 康托·菲茨杰拉德 | $12 → $10 | 维护 | 超重 |
| 02/14/2020 | 574.16% | 康托·菲茨杰拉德 | → $12 | 开始承保 | →超重 |
| 09/13/2019 | 686.52% | 考恩公司 | → $14 | 开始承保 | →跑赢大盘 |
| 08/13/2019 | 517.98% | 派珀·桑德勒 | → $11 | 开始承保 | →超重 |
What is the target price for Cresco Labs (CRLBF)?
Cresco Labs(CRLBF)的目标价是多少？
The latest price target for Cresco Labs (OTCQX: CRLBF) was reported by Cantor Fitzgerald on February 24, 2023. The analyst firm set a price target for $14.25 expecting CRLBF to rise to within 12 months (a possible 700.56% upside). 7 analyst firms have reported ratings in the last year.
Cresco Labs(OTCQX：CRLBF)的最新目标价是由Cantor Fitzgerald于2023年2月24日报道的。这家分析公司将目标价定为14.25美元，预计CRLBF将在12个月内升至(可能上涨700.56%)。去年有7家分析公司公布了评级。
What is the most recent analyst rating for Cresco Labs (CRLBF)?
Cresco Labs(CRLBF)的最新分析师评级是多少？
The latest analyst rating for Cresco Labs (OTCQX: CRLBF) was provided by Cantor Fitzgerald, and Cresco Labs maintained their overweight rating.
Cresco Labs(OTCQX：CRLBF)的最新分析师评级由Cantor Fitzgerald提供，Cresco Labs维持其增持评级。
When is the next analyst rating going to be posted or updated for Cresco Labs (CRLBF)?
Cresco Labs(CRLBF)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cresco Labs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cresco Labs was filed on February 24, 2023 so you should expect the next rating to be made available sometime around February 24, 2024.
分析师在进行了广泛的研究后得出了股票评级，这些研究包括查看公开的财务报表，与Cresco Labs的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Cresco Labs的上一次评级是在2023年2月24日提交的，所以你应该预计下一次评级将在2024年2月24日左右的某个时候公布。
Is the Analyst Rating Cresco Labs (CRLBF) correct?
分析师对Cresco Labs(CRLBF)的评级正确吗？
While ratings are subjective and will change, the latest Cresco Labs (CRLBF) rating was a maintained with a price target of $0.00 to $14.25. The current price Cresco Labs (CRLBF) is trading at is $1.78, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但Cresco Labs(CRLBF)的最新评级保持不变，目标价在0.00美元至14.25美元之间。Cresco Labs(CRLBF)目前的交易价格为1.78美元，在分析师的预测范围内。